Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update -- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalents and Inves...
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results -More than 25 authorized treatment centers (ATCs) activated globally for CASGEVY™ and multiple patients have already had cells collected- -Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70 respectively, across multiple indications- -Clinical trials ongoing for in vivo gene editing product candidates, CTX310™ and CTX320™ targeting ANGPTL3 and Lp(a), respectively- -Expands pipeline with new preclinical programs utilizing lipid nanopar...
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in two upcoming investor conferences: 2024 RBC Capital Markets Global Healthcare ConferenceTuesday, May 14, 2024 at 10:00 a.m. ET in New York, NY Bank of America Healthcare Conference 2024Thursday, May 16, 2024 at 9:20 a.m. PT (12:20 p.m. ET) in La...
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach - ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma - - Expands pipeline with new pre-clinical programs utilizing LNP mediated delivery to the liver for refractory hypertension targeting angiotensinogen (AGT) and acute hepatic porphyria (AHP) targeting 5’-aminolevulinate synthase 1 (ALAS1) - - CTX340™, targeting AGT in the liver, achieved dura...
Two Directors at Kellanova Co sold 87,600 shares at between 60.052USD and 60.923USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
A director at Ionis Pharmaceuticals Inc sold 6,000 shares at 42.713USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Intra-Cellular Therapies Reports First Quarter 2024 Financial Results CAPLYTA Q1 2024 net product sales were $144.8 million, compared to $94.7 million for the same period in 2023, representing a 53% increase CAPLYTA’s strong prescription uptake continues: Q1 2024 CAPLYTA total prescriptions increased 39%, versus the same period in 2023 CAPLYTA 2024 net product sales guidance reiterated at $645 - $675 million Announced robust positive Phase 3 results from Study 501 evaluating lumateperone as an adjunctive therapy to antidepressants in patients with major depressive disorder (MDD) ...
Repligen Corporation to Present at Upcoming May Investor Conferences WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences. RBC Capital Markets’ 2024 Global Healthcare Conference, being held in New York on May 14-15. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 14, 2024 at 10:30 a.m. ET, in addition to a series of one-on-one meetings wit...
Moody's Ratings (Moody's) today assigned a Baa2 rating to Kellanova's proposed €300 million of 10-year senior unsecured notes. Kellanova's Baa2 senior unsecured ratings and Prime-2 commercial paper rating remains unchanged. The outlook is stable. Kellanova will utilize the net proceeds for general...
Moody's Ratings (Moody's) today assigned a Baa2 rating to Kellanova's ("Kellanova") proposed $300 million of 30-year senior unsecured notes. Kellanova's Baa2 senior unsecured ratings and Prime-2 commercial paper rating remains unchanged. The outlook is maintained at stable. Kellanova will utilize ...
Post Holdings Reports Results for the Second Quarter of Fiscal Year 2024; Raises Fiscal Year 2024 Outlook ST. LOUIS, May 02, 2024 (GLOBE NEWSWIRE) -- Post Holdings, Inc. (NYSE:POST), a consumer packaged goods holding company, today reported results for the second fiscal quarter ended March 31, 2024. Highlights: Second quarter net sales of $2.0 billionOperating profit of $190.1 million; net earnings of $97.2 million and Adjusted EBITDA (non-GAAP)* of $345.2 millionRaised fiscal year 2024 Adjusted EBITDA (non-GAAP)* outlook to $1,335-$1,375 million *For additional information regarding n...
Repligen Reports First Quarter 2024 Financial Results Reports first quarter revenue of $151 million Increased new modalities revenue by 16% year-over-yearIncreased Filtration (non-COVID) revenue by 12% year-over-yearAchieved a nine-month book-to-bill ratio of 1.03 WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter (Q1) of 2024, covering the three-month period ended March 31, 2024. The company also reiterated its financial guidan...
Mondelēz International Reports Q1 2024 Results First Quarter Highlights Net revenues increased +1.4% driven by Organic Net Revenue1 growth of +4.2% with underlying Volume/Mix of -2.1%Diluted EPS was $1.04, down 31.6%; Adjusted EPS1 was $0.95, up +16.3% on a constant currency basisCash provided by operating activities was $1.3 billion, up $0.2 billion versus prior year; Free Cash Flow1 was $1.0 billion, up $0.1 billion versus prior yearReturn of capital to shareholders was $1.1 billion CHICAGO, April 30, 2024 (GLOBE NEWSWIRE) -- Mondelēz International, Inc. (Nasdaq: MDLZ) today reported ...
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, May 7, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2024. To attend the live...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.